On 22 January 2026, CPE took part in the Cencora webinar “Navigating global policy shifts: Implications for Europe’s pharmaceutical pricing, market access, and HTA landscape” to discuss how global and European policy developments are reshaping access to medicines, competitiveness, and health systems.
Representing the patient voice, our CEO, Antonella Cardone, focused on what these policy shifts mean in practice for patients across Europe, particularly in the context of cancer care, where inequalities in access and outcomes remain stark.
From Policy Reform to Patient Access
Antonella highlighted cancer inequalities across Europe, with major differences in mortality and in how quickly patients access innovative treatments. These disparities underline the urgent need to reduce complexity and fragmentation in cancer care.
She stressed that EU reforms such as the EU Health Technology Assessment Regulation (HTAR), the Pharmaceutical Legislation, the Critical Medicines Act, and the Biotech Act can significantly improve patient access if aligned with public health goals. By reducing administrative burden and strengthening Europe’s innovation and supply chains, these policies can deliver faster, fairer access, provided that patient needs and equity remain at the centre of decision-making.
Patients as a Balancing Force in Healthcare Policy
Antonella emphasised that patients play a unique balancing role in European healthcare policy, between protecting universal, transparent and democratic health systems and ensuring faster, fairer access to innovation. Persistent fragmentation, despite progress with HTAR, continues to delay access and widen inequalities across Member States, particularly in smaller or less wealthy countries. CPE therefore calls for stronger European-level solutions, including joint procurement and deeper coordination, to safeguard Europe’s health democracy, universal coverage and social protection systems, while ensuring that innovation reaches all patients, wherever they live.
CPE’s Ongoing Commitment
CPE is committed to embedding patient perspectives across EU health policies, from HTA to pharmaceutical reform and competitiveness debates. By advocating for equity and reduced fragmentation, CPE works to ensure a more patient-centred Europe where no cancer patient is left behind.

